Top Biotech Companies in Vancouver (49)
Bold Therapeutics is the world leader in the development of novel metallotherapeutics. Bold Therapeutics' lead program, BOLD-100, has demonstrated positive safety and efficacy in Phase 2 clinical trials in colorectal, biliary tract and gastric cancers, with presentations at ASCO 2024 and ASCO GI 2024. Bold Therapeutics expects to initiate pivotal Phase 3 trials in the near future.
Acuitas is the premier LNP (lipid nanoparticle) technology provider, enabling our partners to advance new therapeutics to address unmet clinical needs. We have developed a broad IP portfolio focussed on the use of LNP technology for nucleic acid therapeutics. This portfolio primarily encompasses novel compositions of matter but also includes novel uses of nucleic acids therapeutics. Our mission is · To...
Quadra is a North American business-to-business distributor of chemicals and ingredients. Founded in 1976, it has grown into a 650-plus-employee organization serving customers across North America. The company combines product distribution with market and service expertise, supporting food and nutrition, industrial applications, and human-health sectors. Quadra emphasizes customer service, innovation, employee development, and continued growth for its partners and customers...
Eurofins Scientific is an international life sciences company, providing a unique range of analytical testing services to clients across multiple industries, to make life and the environment safer, healthier and more sustainable. From the food you eat to the medicines you rely on, Eurofins works with the biggest companies in the world to ensure the products they supply are safe,...
WEX Pharmaceuticals Inc. is a late-stage drug development company in Vancouver, Canada dedicated to the research, development, manufacture, and commercialization of Halneuron®, a new novel non-opioid analgesic. Halneuron® is a highly selective sodium channel blocker and represents a breakthrough in painkiller technology: - Non-addictive, no withdrawal symptoms and no euphoria - No build of up of tolerance over time - A long duration of...
Zucara Therapeutics, a CDRD and MaRS Innovation portfolio company, is developing the first drug therapy to prevent hypoglycemia in people with diabetes. Our first-in-class therapeutic is focused on improving glucagon counterregulation by inhibiting somatostatin which is dysregulated in Type 1 diabetes. Preventing hypoglycemia will dramatically change diabetes disease management, improving both patient health and quality of life.
Lucent Bio is on a mission to accelerate the transition to a sustainable agri-food system through innovative crop input solutions that are climate-positive, non-polluting, and based on circular economy principles. Our products; Soileos, a micronutrient fertilizer, Nutreos, a microplastic-free seed coating; and Agreos, a microplastic-free controlled release fertilizer coating, harness the power of nature to deliver climate-positive results to Agri-food...
Gandeeva Therapeutics is a precision biotechnology company integrating the power of cryogenic electron microscopy (cryo-EM) and machine learning to develop differentiated therapeutics by targeting and modulating key protein-protein interactions. Gandeeva’s structure-guided drug discovery platform encompasses target prediction and validation (SPOTLIGHT™), hit identification by screening virtual and fragment libraries (HYPERFOCUS™), and lead optimization (CRYO-CADD™). Gandeeva has a robust preclinical oncology pipeline...
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to...
Amgen's Top Stability & Growth Strengths
Strong Revenue Growth: Amgen is delivering sustained top-line gains, with Q3 2026 revenue up around 8% to $10.4 billion and full-year guidance of $38.9–$39.7 billion following solid growth in 2024 and 2025. The company also reported rising EPS and operating margin performance in the quarter.
Healthy Cash Flow: Amgen generated $3.7 billion in free cash flow in Q3 2026, supporting balance-sheet flexibility and ongoing investment. The quarter also featured a 47.3% non-GAAP operating margin alongside double-digit EPS growth.
Diversified Revenue Streams: Amgen’s expansion is broad-based, with 17 products posting double-digit growth in Q3 2026, 17 products annualizing above $1 billion, and six core growth drivers expanding 27% to over 70% of product sales. Strength across franchises such as oncology, rare disease, and biosimilars further reduces reliance on any single medicine.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ), is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases—often with limited or no options—so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give...
Jazz Pharmaceuticals, Inc's Top Stability & Growth Strengths
Strong Market Position & Advantage: Jazz is described as a clear leader in rare sleep disorders through its oxybate franchise (Xywav/Xyrem and authorized generics royalties) and in cannabinoid-based epilepsy with Epidiolex surpassing $1B in 2025. Xywav’s idiopathic hypersomnia approval with orphan exclusivity and category-leading revenue reinforce defensibility.
Strong Revenue Growth: Record 2025 revenue around $4.27 billion and a record Q4, with 2026 guidance still pointing up, indicate sustained top-line momentum. Company communications highlight a multi-year streak of annual growth continuing into 2026.
Diversified Revenue Streams: A balanced base with rare sleep revenues above $2B, Epidiolex above $1B, and roughly $1.13B in oncology plus new contributions from Modeyso and royalties shows multiple revenue pillars. Pipeline drivers like zanidatamab and Zepzelca label expansion add additional avenues.
Wesgroup Equipment is an award-winning, full-service construction equipment and material handling dealership operating across Western Canada. Through its family of brands—Williams Machinery, Westerra Equipment, and WE Rent—the company provides sales, rentals, service, and safety training for a wide range of industries, including construction, forestry, agriculture, landscaping, and logistics.
Spring Fertility is a modern fertility center delivering state-of-the-art assisted reproductive services, including IVF, egg and embryo freezing, and genetic testing. They combine top clinical outcomes with a patient-centric, compassionate, and flexible care model, ensuring an inclusive experience for all patients, including the LGBTQ+ community, as they navigate their unique paths to parenthood.
Viking Group Inc. designs, manufactures, and distributes fire protection and life safety systems, offering a comprehensive range of products and global services.
Levitt-Safety is a Canadian safety supplier serving workplaces nationwide. Its offerings include safety equipment, fire-protection solutions, environmental monitoring, worker training, and rental services. The company partners with organizations across Canada to support worker health and safety, providing products and services for fire prevention, workplace protection, and environmental risk management. Its nationwide network supports customers across multiple industries.
HTuO Biosciences is a deep tech company, working at the interface of chemistry, physics and computer programming, to develop an advanced molecular simulation capable of accurately predicting the behaviour of molecules.
Wolseley Canada is the country’s leading national distributor of plumbing, HVAC/R and PVF products. With a network of over 220 branches coast-to-coast, and a national team of sales and service specialists, the Wolseley team is known for their knowledge and expertise that customers have come to rely on for their ever-changing needs. Wolseley has Canada’s largest inventory of leading brand faucets and...
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.
Avivo, a British Columbia-based preclinical-stage company, has identified enzymes that convert the cell surface antigens that determine a person’s blood group to group O, the universal donor type. This innovative platform enables a world where a person’s blood type is no longer the first constraint when they need life-saving organ transplants or blood transfusions. Avivo’s platform will enable healthcare providers...
Virogin Biotech aims to be a global, best-in-class oncolytic virus company that creates impactful drugs for patients of the highest medical need. Our platform technology focuses on creating long-lasting antitumor immunity by capitalizing on a robust, transient antiviral immune response through a synergy with multiple payload expression. Virogin is designing a more potent oncolytic virus, expressing optimized payloads to enhance...
Variational AI has developed Enki, the biopharma industry's first commercially-available foundation model for small molecules. Enki is based on a novel generative AI framework invented by Variational AI that has delivered novel and selective leads to multiple biopharma partners and customers.

































